NQO1 and chronic kidney disease: The third study, using SFN, was conducted in CKD patients not requiring renal replacement therapy and demonstrated an elevated NQO1 mRNA level in monocytes after SFN treatment (p < 0.05) compared to baseline (which was lower than in the placebo group).